Explore
Validate
Learn
Western blot
ELISA
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN560913 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Forkhead Box C2 (MFH-1, Mesenchyme Forkhead 1) (FOXC2) (AA 421-501), (partial) antibody
- Antibody type
- Monoclonal
- Reactivity
- Human
- Host
- Mouse
- Epitope
- AA 421-501, partial
- Isotype
- IgG
- Antibody clone number
- 2H3
- Vial size
- 100 μg
- Storage
- Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
- Handling
- Aliquot to avoid repeated freezing and thawing.
Submitted references FOXC2 expression is associated with tumor proliferation and invasion potential in oral tongue squamous cell carcinoma.
MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol.
FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma.
Imayama N, Yamada S, Yanamoto S, Naruse T, Matsushita Y, Takahashi H, Seki S, Fujita S, Ikeda T, Umeda M
Pathology oncology research : POR 2015 Jul;21(3):783-91
Pathology oncology research : POR 2015 Jul;21(3):783-91
MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol.
Yu YH, Chen HA, Chen PS, Cheng YJ, Hsu WH, Chang YW, Chen YH, Jan Y, Hsiao M, Chang TY, Liu YH, Jeng YM, Wu CH, Huang MT, Su YH, Hung MC, Chien MH, Chen CY, Kuo ML, Su JL
Oncogene 2013 Jan 24;32(4):431-43
Oncogene 2013 Jan 24;32(4):431-43
FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma.
Nishida N, Mimori K, Yokobori T, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y, Mori M
Annals of surgical oncology 2011 Feb;18(2):535-42
Annals of surgical oncology 2011 Feb;18(2):535-42
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- ELISA
